NewAmsterdam Pharma (NAMS)

• Market cap: $4.22B
• 1 day: 2.99%
• 5 days: 3.85%
• 1 month: -2.77%
• 3 months: 53.99%
• 6 months: 77.13%
• Year to date: 43.49%
• 1 year: 48.47%
• 5 years: 259.9%
• 10 years: 259.9%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77